Increased Risk of Hypertension with Enzalutamide in Prostate Cancer: A Meta-Analysis

Hypertension is associated with enzalutamide in the treatment of prostate cancer. We performed a meta-analysis of randomized clinical trials to determine the risk of hypertension. Databases including Pubmed and Google scholar were searched to identify randomized clinical trials with enzalutamide. A total of seven studies including 7347 patients were selected. The overall incidences of all-grade and high-grade hypertension were 11.9% (95%% CI: 8.8?16.0%) and 4.9% (95%% CI: 3.5?6.8%) respectively, with a relative risk of 2.82 (95%% CI: 2.34?3.38, p?